117 related articles for article (PubMed ID: 9808570)
1. Evidence for an upper affinity threshold for anti-IgM-induced apoptosis in a human B-cell lymphoma.
Mongini PK; Liu Q; Vilensky MA; Highet PF; Inman JK
Blood; 1998 Nov; 92(10):3756-71. PubMed ID: 9808570
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells.
Cragg MS; Zhang L; French RR; Glennie MJ
Br J Cancer; 1999 Feb; 79(5-6):850-7. PubMed ID: 10070880
[TBL] [Abstract][Full Text] [Related]
3. A monovalent C mu 4-specific ligand enhances the activation of human B cells by membrane IgM cross-linking ligands.
Mongini PK; Blessinger CA; Chiorazzi N; Rajaram N; Rudich SM
Int Immunol; 1995 Feb; 7(2):317-30. PubMed ID: 7734425
[TBL] [Abstract][Full Text] [Related]
4. Anti-IgM-mediated B cell signaling. Molecular analysis of ligand binding requisites for human B cell clonal expansion and tolerance.
Rudich SM; Roux KH; Winchester RJ; Mongini PK
J Exp Med; 1988 Jul; 168(1):247-66. PubMed ID: 2456368
[TBL] [Abstract][Full Text] [Related]
5. Differential regulatory effects of cAMP-elevating agents on human normal and neoplastic B cell functional response following ligation of surface immunoglobulin and CD40.
Kelly K; Knox KA
Cell Immunol; 1995 Nov; 166(1):93-102. PubMed ID: 7585986
[TBL] [Abstract][Full Text] [Related]
6. Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
Chang CH; Wang Y; Gupta P; Goldenberg DM
MAbs; 2015; 7(1):199-211. PubMed ID: 25484043
[TBL] [Abstract][Full Text] [Related]
7. A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death.
Lens SM; Tesselaar K; den Drijver BF; van Oers MH; van Lier RA
J Immunol; 1996 Jan; 156(2):507-14. PubMed ID: 8543800
[TBL] [Abstract][Full Text] [Related]
8. The influence of avidity on signaling murine B lymphocytes with monoclonal anti-IgM antibodies. Effects of B cell proliferation versus growth inhibition (tolerance) of an immature B cell lymphoma.
Udhayakumar V; Kumar L; Subbarao B
J Immunol; 1991 Jun; 146(12):4120-9. PubMed ID: 2040794
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis of Burkitt's lymphoma cells induced by specific interaction of surface IgM with a self-antigen: implications for lymphomagenesis in acquired immunodeficiency syndrome.
Roncella S; Cutrona G; Favre A; Ulivi M; Fais F; Signorini A; Grossi CE; Chiorazzi N; Ferrarini M
Blood; 1996 Jul; 88(2):599-608. PubMed ID: 8695808
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.
Shan D; Ledbetter JA; Press OW
Blood; 1998 Mar; 91(5):1644-52. PubMed ID: 9473230
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of antigen receptor-dependent apoptosis of human B lymphoma cells probed with a panel of 27 monoclonal antibodies.
Grafton G; Goodall M; Gregory CD; Gordon J
Cell Immunol; 1997 Nov; 182(1):45-56. PubMed ID: 9427809
[TBL] [Abstract][Full Text] [Related]
12. Immunomagnetic removal of B-lymphoma cells using a novel mono-sized magnetizable polymer bead, M-280, in conjunction with primary IgM and IgG antibodies.
Kvalheim G; Fjeld JG; Pihl A; Funderud S; Ugelstad J; Fodstad O; Nustad K
Bone Marrow Transplant; 1989 Sep; 4(5):567-74. PubMed ID: 2790334
[TBL] [Abstract][Full Text] [Related]
13. Affinity requirements for induction of sequential phases of human B cell activation by membrane IgM-cross-linking ligands.
Mongini PK; Blessinger CA; Dalton JP
J Immunol; 1991 Mar; 146(6):1791-800. PubMed ID: 2005379
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the domain specificity of various murine anti-human IgM monoclonal antibodies differing in human B lymphocyte signaling activity.
Rudich SM; Mihaesco E; Winchester R; Mongini PK
Mol Immunol; 1987 Aug; 24(8):809-20. PubMed ID: 2443845
[TBL] [Abstract][Full Text] [Related]
15. CD40-triggered protein tyrosine phosphorylation on Vav and on phosphatidylinositol 3-kinase correlates with survival of the Ramos-Burkitt lymphoma B cell line.
Padmore L; An S; Gunby RH; Kelly K; Radda GK; Knox KA
Cell Immunol; 1997 May; 177(2):119-28. PubMed ID: 9178638
[TBL] [Abstract][Full Text] [Related]
16. In vivo study of mIgM and mIgD cross-linking on murine B cells.
Denis O; Macedo-Soares F; Latinne D; Nisol F; Bazin H
Scand J Immunol; 1994 Jun; 39(6):625-32. PubMed ID: 8009179
[TBL] [Abstract][Full Text] [Related]
17. Specificity and biologic activities of novel anti-membrane IgM antibodies.
Welt RS; Welt JA; Kostyal D; Gangadharan YD; Raymond V; Welt S
Oncotarget; 2016 Nov; 7(46):74701-74723. PubMed ID: 27732950
[TBL] [Abstract][Full Text] [Related]
18. Difference in apoptosis induction between surface IgD and IgM.
Peckham D; Andersen-Nissen E; Finkelman FD; Stunz LL; Ashman RF
Int Immunol; 2001 Mar; 13(3):285-95. PubMed ID: 11222497
[TBL] [Abstract][Full Text] [Related]
19. Cross-linking of surface IgM in the Burkitt's lymphoma cell line ST486 provides protection against arsenite- and stress-induced apoptosis that is mediated by ERK and phosphoinositide 3-kinase signaling pathways.
Muscarella DE; Bloom SE
J Biol Chem; 2003 Feb; 278(6):4358-67. PubMed ID: 12464623
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of CPP32 blocks surface IgM-mediated apoptosis and D4-GDI cleavage in human BL60 Burkitt lymphoma cells.
Rickers A; Brockstedt E; Mapara MY; Otto A; Dörken B; Bommert K
Eur J Immunol; 1998 Jan; 28(1):296-304. PubMed ID: 9485209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
